Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28950438 | 0.94 | L3MBTL1 (0.49) | KMT2AL3MBTL1PDE4BCTSL | |
| SCHEMBL23971172 | 0.94 | L3MBTL1 (0.49) | KMT2AL3MBTL1PDE4BCTSL | |
| SCHEMBL34466985 | 0.94 | L3MBTL1 (0.49) | KMT2AL3MBTL1PDE4BCTSL | |
| SCHEMBL25907337 | 0.92 | ALDH1A1 (0.47) | KMT2AL3MBTL1PDE4BCTSLNPC1 | |
| SCHEMBL6619512 | 0.90 | PDE4B (0.44) | KMT2AL3MBTL1PDE4BCTSLDRD2 | |
| SCHEMBL6623570 | 0.90 | PDE4B (0.47) | KMT2AL3MBTL1PDE4BCTSLNPC1 | |
| SCHEMBL6623558 | 0.90 | PDE4B (0.47) | KMT2AL3MBTL1PDE4BCTSLNPC1 | |
| SCHEMBL6623564 | 0.90 | PDE4B (0.47) | KMT2AL3MBTL1PDE4BCTSLNPC1 | |
| SCHEMBL141501 | 0.89 | ALDH1A1 (0.53) | CTSLNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7366503 | 0.88 | PDE4B (0.44) | KMT2AL3MBTL1PDE4BCTSLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-7977327-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1757598-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | AQP1, GLUL, GATD3 | KMT2A 1856/4885L3MBTL1 2601/4885PDE4B 1718/4885 |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | QPCT, GMPS, QPCTL | KMT2A 2369/4885L3MBTL1 3444/4885PDE4B 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.